Research Presentation Sessions: Breast
RPS 802 - Image-based assessment in primary systemic treatment in breast cancer
Lectures
1
Imaging and pathologic complete response after neoadjuvant therapy in breast cancer: are we ready to avoid surgery? Results from a prospective single-institution study
07:00Filippo Pesapane, Milan / IT
2
Prognostic value of achieving metabolic complete response of the primary tumour on dedicated breast 18F-FDG PET/MRI post-neoadjuvant chemo(targeted) therapy in breast cancer patients
07:00Melissa Lenaerts, Peer / BE
3
Percentage functional tumour volume on pretreatment MRI within triple-negative breast cancer predicts pathologic complete response to combination neoadjuvant immunotherapy and chemotherapy
07:00Robert Jared Weinfurtner, Tampa / US
4
MRI accurately predicts pCR in patients with HER2+ breast cancer treated with neoadjuvant immunotherapy followed by neoadjuvant chemotherapy
07:00Robert Jared Weinfurtner, Tampa / US
5
Positron emission mammography (PEM) evaluation in the assessment of response to neoadjuvant chemotherapy and prediction of residual disease in breast cancer
07:00Yassmin Mohamed Nada, Cairo / EG
6
Neoadjuvant chemotherapy monitoring with contrast-enhanced ultrasound in patients with breast cancer
07:00Iva Biondić Špoljar, Zagreb / HR
7
The use of targeted axillary dissection after neoadjuvant treatment in breast cancer patients with axillary lymph node involvement
07:00Liam Bell, Barcelona / ES
8
Implementation of the MARI treatment protocol in clinically node-positive breast cancer patients: correlation with axillary ultrasound and 18F-FDG PET/CT nodal findings
07:00Thiemo van Nijnatten, Maastricht / NL
9
Moderation
00:00Fleur Kilburn-Toppin, Cambridge / UK